Wedbush Analyst Raises Larimar Therapeutics FY2028 EPS Estimate to $0.70

Summary

Wedbush analyst increased Larimar Therapeutics’ (NASDAQ: LMRR) FY 2028 EPS estimate from $0.68 to $0.70. The consensus earnings estimate for the current year remains at a loss of $1.15 per share. Other brokerages have also issued buy ratings, with an average target price of $20.13. However, LMRR’s stock opened at $2.28, down 10.2%. The company focuses on developing treatments for rare diseases, with its primary product candidate in Phase 2 clinical trials. Market Beat

Impact Analysis

The event is classified at the company level, as it revolves around Larimar Therapeutics’ financial performance and market perception. The analyst’s upward revision of EPS estimates implies increased optimism about the company’s future prospects. Despite this, the stock price decline suggests investor skepticism potentially driven by recent poor earnings results, where the company reported a worse-than-expected quarterly loss of $0.45 per share compared to the anticipated loss of $0.32 per share. Market Beat+ 2 The sharp contrast between the analyst’s optimism and the market’s negative reaction indicates divergent views on the company’s valuation and growth potential. First-order effects include the immediate stock price decline. Second-order effects could involve reassessment by investors of the company’s long-term potential and further scrutiny of clinical trial progress. Investment opportunities could arise if the market sentiment shifts positively as clinical data or future earnings improve. Market Beat